Nuvilex EBITDA 2010-2024 | PMCB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuvilex ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuvilex ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.8B
Chugai Pharmaceutical (CHGCY)	$66.9B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$20B
Astellas Pharma (ALPMY)	$17.7B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$16B
Neurocrine Biosciences (NBIX)	$15.3B
Shionogi (SGIOY)	$12.5B
Orion OYJ (ORINY)	$7.5B
Madrigal Pharmaceuticals (MDGL)	$7.1B
Stevanato Group S.p.A (STVN)	$6.5B
Corcept Therapeutics (CORT)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.9B
Grifols, S.A (GRFS)	$4.8B
Crinetics Pharmaceuticals (CRNX)	$3.7B
Catalyst Pharmaceuticals (CPRX)	$2.9B
Recursion Pharmaceuticals (RXRX)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Centessa Pharmaceuticals (CNTA)	$2.2B
Soleno Therapeutics (SLNO)	$2.1B
Hypermarcas (HYPMY)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Indivior (INDV)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Evotec AG (EVO)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.4B